Could you tell me my balance, please?
klonopin and your liver First, the good news: In a Phase III study on 118 patients, those who received a cocktail of Oncolytics' Reolysin, carboplatin and paclitaxel charted median progression-free survival of 94 days, beating out the 50-day mark for patients who got just the two cancer drugs. Furthermore, of the 88 patients who didn't get further treatment after the trial, those in the treatment arm posted a median overall survival of 150 days, above the 115 days of the control arm.